Maryam Abbasi

Ms. Maryam Abbasi


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2025 in Medicine
Verified
Journal Article
Open access
MQMuhammad Saeed Qazi
Muhammad Saeed Qazi
AAAwais Ahmad
Awais Ahmad
MMMahreen Mukhtiar
Mahreen Mukhtiar
RNRizwana Noor
Rizwana Noor
HAHassan Ahmed
Hassan Ahmed
MEMohammed Mahmmoud Fadelallah Eljack
Mohammed Mahmmoud Fadelallah Eljack
Background: Erdheim–Chester disease (ECD) is characterized by the excessive production and accumulation of histiocytes, particularly foamy histiocytes encircled by fibrosis, in various organs. ECD can affect a person’s long bones, skin, lungs, brain, heart, and other tissues and organs. Methods: In February 2024, we conducted a thorough literature search on main databases to find studies published between 2021 and 2024. We used keywords like “ECD CNS,” “ECD Neuro,” “Erdheim Chester Disease CNS,” “histiocytosis,” and “Erdheim Chester Disease Neurology.” We first produced 461 articles and then limited the selection process to 29 articles using an English language filter and an abstract analysis. In the end 16 articles were added in the review on ECD with neurological symptoms. Results: Ataxia, cranial neuropathies, and cognitive impairment were the main clinical findings. Histopathology showed that 88% of the cases had histiocyte infiltrates with CD68 + histiocytes, 50% had a BRAF mutation, and 83.3% had an expanding mass. The most common treatment was vemurafenib, followed by steroids, surgery, and chemotherapy. Results revealed 15.78% mortality, 26.31% progression, and 31.57% improvement or stabilization. In most cases, steroid medication proved useless; however, vemurafenib and radiation therapy helped some patients’ symptoms. Conclusion: An early diagnosis of the disease is important for timely intervention, to prevent fatal outcomes. Vemurafenib was the only drug which proved its efficacy against the disease, as compared to other drugs. This study presents valuable insights for the neurology of ECD and highlights the benefits of a comprehensive management for this complex condition.

18 April 2020 in Cureus
Verified
Journal Article
Open access
PDF file
SAShahid Ahmed
Shahid Ahmed
HSHafeezullah Shaikh
Hafeezullah Shaikh
SJSajjad Jamil
Sajjad Jamil
HAHamid Ali
Hamid Ali
MAMaryam Abbasi
Maryam Abbasi
Background: The prevalence of obesity is on the rise globally. Pakistan ranks ninth out of 188 countries in terms of obesity. Literature regarding any potential role of obesity in gastrointestinal manifestations is limited. Besides, scarce information is available on possible connection between obesity and gastrointestinal pathology. This research, therefore, explores the impact of body mass index (BMI) on gastrointestinal symptoms and endoscopic discoveries. Methods: A cross-sectional study was conducted at Darul Sehat Hospital, Zubaida Medical Centre, and Liaquat National Hospital & Medical College, Karachi, Pakistan from 1st July 2017 to 30th November 2018. Patients scheduled to undergo endoscopy were surveyed before the procedure in which they were asked about demographics, comorbid, and gastrointestinal manifestations. The association between BMI and endoscopic findings and related gastrointestinal symptoms was assessed using Pearson chi square test and binary logistic regression. The significance level was set at 0.05. Results: A total of 2148 subjects were included in the study out of which 20.2% were overweight (BMI 23-24.9) and 20.9% subjects were obese (BMI >25). Both the gastrointestinal symptoms and endoscopic findings were found to be significantly associated with the BMI (p<0.05 for both). Moreover, binary logistic regression revealed obesity to be a significant contributor of abnormal endoscopic findings (adjusted odds ratio, AOR, 2.93; 95% confidence interval, CI, 2.35-3.65). Conclusion: Based on the study results, obesity was identified as a risk factor associated with gastrointestinal symptoms like gastro esophageal reflux disease (GERD) and other related gastrointestinal conditions such as erosive gastritis, duodenal ulcers, reflux esophagitis, and large hiatal hernia.